PLCXD2

Across TCGA pan-cancer cohorts, PLCXD2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of PLCXD2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PLCXD2 RNA is repressed in tumor relative to normal tissue. In most cancer types PLCXD2 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

KIRC, KICH, and HNSC are the cancer types where PLCXD2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLCXD2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−1.657	<.001	11	view →
KICH	Male	II,III,IV	−1.892	<.001	10	view →
HNSC	Male	IV	+1.795	<.001	10	view →
LUAD	Female	III,IV	−1.278	<.001	9	view →
KIRP	Male	III,IV	−1.299	<.001	8	view →
THCA	All	II,III,IV	−0.521	<.001	8	view →
UCEC	All	All	+0.218	.009	6	view →
BLCA	All	III,IV	+1.099	.009	3	view →
CHOL	All	II,III,IV	−0.875	.049	2	view →
PRAD	All	All	−0.259	.020	2	view →
LUSC	Male	III,IV	−1.375	.028	1	view →
LIHC	All	II,III,IV	−0.453	.024	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

PLCXD2–KIRC

Open the KIRC breakdown →